XML 60 R46.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Collaborative Development Contracts (Details) $ in Thousands | 1 Months Ended |  |
--- | --- | --- | ---
Jan. 31, 2022 USD ($) program performance_obligation phenomap | Mar. 31, 2024 USD ($) | Dec. 31, 2023 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Unearned revenue |  | $ 36,618 | $ 36,426
Collaborative arrangement |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Unearned revenue |  | $ 6,500 |
Roche and Genentech | Collaborative arrangement |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Remaining unearned revenue | $ 150,000 |  |
Number of performance obligations under the agreement (in performance obligations) | performance_obligation | 3 |  |
Remaining performance obligation revenue | $ 150,000 |  |
Roche and Genentech | Collaborative arrangement | Phenomaps creation |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Research project, fees and milestones payments receivable for an option on a lead series | $ 250,000 |  |
Number of eligible phenomaps (in phenomaps) | phenomap | 16 |  |
Roche and Genentech | Collaborative arrangement | Phenomaps raw images |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Research project, fees and milestones payments receivable for an option on a lead series | $ 250,000 |  |
Number of eligible phenomaps (in phenomaps) | phenomap | 12 |  |
Roche and Genentech | Collaborative arrangement | Developed and commercialized programs |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Research project, fees and milestones payments receivable for an option on a lead series | $ 300,000 |  |
Number of projects that may be initiated (in projects) | program | 40 |  |
Roche and Genentech | Collaborative arrangement | Gastrointestinal cancer |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Number of performance obligations under the agreement (in performance obligations) | performance_obligation | 1 |  |
Roche and Genentech | Collaborative arrangement | Neuroscience |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |
Number of performance obligations under the agreement (in performance obligations) | performance_obligation | 2 |  |

X
- Definition Contract With Customer, Maximum Accepted Product + References No definition available. + Details
Name: | rxrx_ContractWithCustomerMaximumAcceptedProduct
Namespace Prefix: | rxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Performance Obligation, Number Of Obligations + References No definition available. + Details
Name: | rxrx_RevenuePerformanceObligationNumberOfObligations
Namespace Prefix: | rxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Number Of Projects That May Be Initiated + References No definition available. + Details
Name: | rxrx_RevenueRemainingPerformanceObligationNumberOfProjectsThatMayBeInitiated
Namespace Prefix: | rxrx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration Amount + References No definition available. + Details
Name: | rxrx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix: | rxrx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rxrx_RocheAndGenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsCreationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_PhenomapsRawImagesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_DevelopedAndCommercializedProgramsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_GastrointestinalCancerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rxrx_RevenueRemainingPerformanceObligationAxis=rxrx_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |